

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

|   |   |   |   |
|---|---|---|---|
| 1. Name and Address of Reporting Person<br>Drapé Eric                               | 2. Date of Event Requiring Statement (Month/Day/Year)<br>10/02/2019 | 3. Issuer Name and Ticker or Trading Symbol<br>Teva Pharmaceutical Industries Ltd. [TEVA]   |   |
| (Last) (First) (Middle)<br>C/O Teva Pharmaceutical Industries Ltd. , 5 Basel Street |   | 4. Relationship of Reporting Person(s) to Issuer<br>(Check all applicable)<br>____ Director ____ 10% Owner<br><u>X</u> Officer (give title below)<br>Executive VP Global Operations | 5. If Amendment, Date Original Filed(Month/Day/Year)  |
| (Street)<br>Petach Tikva L3 4951033   |   |   | 6. Individual or Joint/Group Filing (Check Applicable Line)<br><u>X</u> Form filed by One Reporting Person<br>____ Form filed by More than One Reporting Person |
| (City) (State) (Zip)  |   |   |   |

**Table I - Non-Derivative Securities Beneficially Owned**

| 1.Title of Security<br>(Instr. 4) | 2. Amount of Securities Beneficially Owned<br>(Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I)<br>(Instr. 5) | 4. Nature of Indirect Beneficial Ownership<br>(Instr. 5) |
|-----------------------------------|--|---|--|
| Ordinary Shares <sup>(1)</sup>    | 17,195   | D   |  |

**Table II - Derivative Securities Beneficially Owned ( e.g., puts, calls, warrants, options, convertible securities)**

| 1. Title of Derivative Security<br>(Instr. 4) | 2. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                    | 3. Title and Amount of Securities<br>Underlying Derivative Security<br>(Instr. 4) |                               | 4. Conversion or<br>Exercise Price of<br>Derivative<br>Security | 5. Ownership<br>Form of<br>Derivative<br>Security: Direct<br>(D) or Indirect (I)<br>(Instr. 5) | 6. Nature of Indirect Beneficial<br>Ownership<br>(Instr. 5) |
|---|--|--------------------|---|-------------------------------|---|--|---|
|   | Date<br>Exercisable  | Expiration<br>Date | Title   | Amount or<br>Number of Shares |   |  |   |
| Stock Options (right to buy)                  | (2)  | 12/09/2023         | Ordinary<br>Shares <sup>(1)</sup>   | 25,005                        | \$40.15   | D  |   |
| Stock Options (right to buy)                  | (3)  | 03/11/2024         | Ordinary<br>Shares <sup>(1)</sup>   | 15,002                        | \$48.76   | D  |   |
| Stock Options (right to buy)                  | (4)  | 02/11/2025         | Ordinary<br>Shares <sup>(1)</sup>   | 54,623                        | \$57.35   | D  |   |
| Stock Options (right to buy)                  | (5)  | 02/11/2026         | Ordinary<br>Shares <sup>(1)</sup>   | 54,950                        | \$55.75   | D  |   |
| Stock Options (right to buy)                  | (6)  | 02/14/2027         | Ordinary<br>Shares <sup>(1)</sup>   | 62,364                        | \$34.9  | D  |   |
| Stock Options (right to buy)                  | (7)  | 09/18/2027         | Ordinary<br>Shares <sup>(1)</sup>   | 33,339                        | \$16.99   | D  |   |
| Stock Options (right to buy)                  | (8)  | 02/08/2028         | Ordinary<br>Shares <sup>(1)</sup>   | 50,231                        | \$18.61   | D  |   |
| Restricted Share Units                        | (9)  | (9)                | Ordinary<br>Shares <sup>(1)</sup>   | 7,852                         | (10)  | D  |   |
| Restricted Share Units                        | (11)   | (11)               | Ordinary<br>Shares <sup>(1)</sup>   | 19,702                        | (10)  | D  |   |
| Restricted Share Units                        | (12)   | (12)               | Ordinary<br>Shares <sup>(1)</sup>   | 35,820                        | (10)  | D  |   |

**Explanation of Responses:**

- (1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- (2) Stock options were granted on December 9, 2013, with 8,335 having vested on each of December 9, 2015, December 9, 2016 and December 9, 2017.

- (3) Stock options were granted on March 12, 2014, with 5,000 having vested on each of March 12, 2015 and March 12, 2016 and 5,002 having vested on March 12, 2017.
- (4) Stock options were granted on February 12, 2015, with 18,207 having vested on each of February 12, 2017 and February 12, 2018 and 18,209 on February 12, 2019.
- (5) Stock options were granted on February 12, 2016, with 18,316 having vested on each of February 12, 2018 and February 12, 2019 and 18,318 vesting on February 12, 2020.
- (6) Stock options were granted on February 14, 2017, with 20,788 having vested on February 14, 2019, and 20,788 vesting on each of February 14, 2020 and February 14, 2021.
- (7) Stock options were granted on September 18, 2017 and vested on September 18, 2019.
- (8) Stock options were granted on February 9, 2018, with 16,743 vesting on each of February 9, 2020 and February 9, 2021 and 16,745 vesting on February 9, 2022.
- (9) Restricted share units were granted on February 14, 2017, with 3,926 vesting on each of February 14, 2020 and February 14, 2021.
- (10) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- (11) Restricted share units were granted on February 9, 2018, with 6,567 vesting on each of February 9, 2020 and February 9, 2021 and 6,568 vesting on February 9, 2022.
- (12) Restricted share units were granted on March 4, 2019, with 11,940 vesting on each of March 4, 2021, March 4, 2022 and March 4, 2023.

/s/ Dov Bergwerk, as attorney-in-fact for Eric Drape  
\*\*Signature of Reporting Person

10/15/2019  
Date

\* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

POWER OF ATTORNEY  
FOR SECTION 16 REPORTING OBLIGATIONS

KNOW ALL BY THESE PRESENTS, that the undersigned hereby makes, constitutes and appoints Dov Bergwerk, Dikla Tadmor, Netanel Derovan and Shira Aran-Porat signing singly, as the undersigned's true and lawful attorney-in-fact, with full power and authority as hereinafter described on behalf of and in the name, place and stead of the undersigned to:

- (1) prepare, execute, acknowledge, deliver and file Forms 3, 4, and 5 (including any amendments thereto) with respect to the securities of Teva Pharmaceutical Industries Limited, a company incorporated under the law of Israel, or any successor thereto (the "Company"), with the U.S. Securities and Exchange Commission, any national securities exchanges and the Company, as considered necessary or advisable under Section 16(a) of the Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder, as amended from time to time (the "Exchange Act");
- (2) seek or obtain, as the undersigned's representative and on the undersigned's behalf, information of transactions in the Company's securities from any third-party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to the undersigned and approves and ratifies any such release of information; and
- (3) perform any and all other acts which in the discretion of such attorney-in-fact is necessary or desirable for and on behalf of the undersigned in connection with the foregoing.

The undersigned acknowledges that:

- (1) this Power of Attorney authorizes, but does not require, such attorney-in-fact to act in his or her discretion on information provided to such attorney-in-fact without independent verification of such information;
- (2) any documents prepared, executed, acknowledged and/or delivered by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney will be in such form and will contain such information and disclosure as such attorney-in-fact, in his or her discretion, deems necessary or desirable;
- (3) neither the Company nor such attorney-in-fact assumes (i) any liability for the undersigned's responsibility to comply with the requirement of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act; and
- (4) this Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under the Exchange Act, including without limitation the reporting requirements under Section 16 of the Exchange Act.

The undersigned hereby gives and grants the foregoing attorney-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary or appropriate to be done in and about the foregoing matters as fully to all intents and purposes as the undersigned might or could do if present, hereby ratifying all that such attorney-in-fact of, for and on behalf of the undersigned, shall lawfully do or

cause to be done by virtue of this Power of Attorney.

This Power of Attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to such attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 7th day of October, 2019.

By: /s/ Eric Drape

Name: Eric Drape

Title: Executive VP, Global Operations